Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Liddle syndrome in which the cause of the disease is a mutation in the SCNN1G gene.
Features include always present findings: Decreased circulating renin concentration, Hypertension, Metabolic alkalosis, and Hypokalemia; and sometimes findings: Decreased circulating aldosterone concentration.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 1 | Hypertension |
SCNN1G function has not been fully characterized.
Liddle syndrome 2 is associated with mutations in the SCNN1G gene on chromosome 16.
Genetic testing for SCNN1G is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Liddle syndrome 2 has been reported in the published literature.
Phenotype severity distribution: 4 always present features.
No clinical trials have been registered for Liddle syndrome 2.
10 publications have been identified in PubMed for Liddle syndrome 2. Research spans Review / Meta-Analysis (40%), Case Report / Case Series (20%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 | 40% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 1:04 AM UTC
Online Mendelian Inheritance in Man
Common questions about Liddle syndrome 2
1 |
Metabolic alkalosis |
2 |
20% |
Laboratory research | 2 | 20% |
Testing and diagnosis research | 1 | 10% |
Disease patterns and progression | 1 | 10% |
Abd El-Aziz TM (2026). [PMID: 41498836](https://pubmed.ncbi.nlm.nih.gov/41498836/). *Purinergic Signal*. [Review / Meta-Analysis]
Ripeau DB (2025). [PMID: 40990635](https://pubmed.ncbi.nlm.nih.gov/40990635/). *J Hypertens*. [Review / Meta-Analysis]
Darko-Boateng A (2025). [PMID: 41353348](https://pubmed.ncbi.nlm.nih.gov/41353348/). *Nat Commun*. [Basic Science / Preclinical]
Tang Q (2025). [PMID: 40696293](https://pubmed.ncbi.nlm.nih.gov/40696293/). *BMC Nephrol*. [Review / Meta-Analysis]
Scott ML (2025). [PMID: 40952999](https://pubmed.ncbi.nlm.nih.gov/40952999/). *Am J Physiol Renal Physiol*. [Basic Science / Preclinical]
Prabowo NA (2024). [PMID: 39816126](https://pubmed.ncbi.nlm.nih.gov/39816126/). *Narra J*. [Case Report / Case Series]
Granhøj J (2024). [PMID: 38265765](https://pubmed.ncbi.nlm.nih.gov/38265765/). *Clin J Am Soc Nephrol*. [Review / Meta-Analysis]
Sakoda R (2024). [PMID: 39284704](https://pubmed.ncbi.nlm.nih.gov/39284704/). *Drug Metab Dispos*. [Diagnostic / Biomarker]
Liddle D (2024). [PMID: 38403073](https://pubmed.ncbi.nlm.nih.gov/38403073/). *J Cardiovasc Magn Reson*. [Epidemiology / Natural History]
Salcuni AS (2024). [PMID: 38778592](https://pubmed.ncbi.nlm.nih.gov/38778592/). *Endocr Metab Immune Disord Drug Targets*. [Case Report / Case Series]